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Abstract Pro-apoptotic functions of the BH3-only protein
BAD are negatively regulated by survival signal-mediated phos-
phorylation at several serine residues. Recently, we found that
the mutant BAD (BADD119G) with an amino acid substitution
of Asp (Asp119 to Gly) within the BH3 domain displays strong
pro-apoptotic activity in serum-starved COS-7 cells, although it
cannot interact with Bcl-2. Here, we demonstrate that the
BADD119G loses phosphorylation-mediated negative regula-
tion. Importantly, pro-apoptotic activity of wild-type BAD
(BADwt) was strongly suppressed by co-transfection with con-
stitutively active Akt (CA-Akt) cDNA, whereas that of
BADD119G was not. In these transfectants, BADD119G phos-
phorylation was barely detectable at serine residues (S75 and
S99), although BADwt phosphorylation was clearly increased
by CA-Akt. In addition, various external stimuli UV, TPA
and forskolin could not phosphorylate BADD119G neither at
S75, S99 nor S118 in COS-7 cells. However, in vitro kinase
assay revealed that catalytic protein kinase A (PKA) strongly
phosphorylated both BADs at S75 and S118, excluding the
possibility that the target sequence of PKA was disrupted by
mutation at S119. Furthermore, as a result of disrupted phos-
phorylation, BADD119G could not physically interact with 14-
3-3. Taken together, disruption of phosphorylation-mediated
negative regulation may explain, at least in part, the strong
pro-apoptotic functions of BADD119G, and suggest a role for
the BH3 domain in phosphorylation events.
7 2003 Published by Elsevier B.V. on behalf of the Federation
of European Biochemical Societies.
Key words: BAD; BH3 domain; Mutation; PKA;
14-3-3; Phosphorylation; Apoptosis
1. Introduction
Bcl-2 family proteins share homologous structures, BH1 to
BH4 domains [1,2]. Among these regions, the BH3 domain is
responsible for interaction with other Bcl-2 family proteins
and plays pivotal roles in regulating apoptosis [3]. Since all
BH3-only proteins identi¢ed so far ^ for example, BAD, Bid,
Bik, Bim, Bmf, BNIP3, Hrk, and Noxa ^ can interact with
apoptosis-related molecules, and function as pro-apoptotic
molecules, the region is believed to be crucial for pro-apopto-
tic functions. However, there are some data suggesting that
the BH3 domain of the pro-apoptotic proteins may not di-
rectly serve pro-apoptotic functions. Indeed, functional anal-
ysis of a mutant Bik has revealed that hetero-dimerization
with survival proteins alone is insu⁄cient for its cell death
activity [4]. Moreover, a mutation within the BH3 domain
of BAX disrupts its ability to interact with Bcl-2 and Bcl-
XL, without disturbing its ability to induce apoptosis [5].
These accumulating data suggest that pro-apoptotic molecules
can introduce death signals independently of the BH3-medi-
ated interaction, and the functions of the BH3 domain may
vary among the pro-apoptotic proteins.
A BH3-only protein, BAD, is unique, since its functions are
tightly regulated by serine phosphorylation [6,7]. Biologically
active BAD is a dephosphorylated form and interacts with
either Bcl-2 or Bcl-XL to neutralize their anti-apoptotic func-
tions, and this neutralization is believed to account for its pro-
apoptotic functions. Inactive BAD is highly phosphorylated
by survival signals and binds to 14-3-3 sca¡old proteins and
thus cannot interact with Bcl-2 or Bcl-XL [7,8]. Thus, phos-
phorylation and dephosphorylation of BAD can switch its
binding target and determine its pro-apoptotic activity. To
date, four serine residues S112, 136, 155 and 170 in murine
BAD are known to be phosphorylated in response to survival
signals. Phosphorylation of BAD at S112 mainly depends
upon a mitogen-activated protein kinase/extracellular signal-
regulated kinase kinase-mediated phosphorylation event or its
downstream p90Rsk-mediated pathway [9,10]. Phosphoryla-
tion of BAD at S136 requires the serine/threonine kinase pro-
tein kinase B (Akt) [11,12], while BAD phosphorylation at
S155 mainly requires protein kinase A (PKA) [13]. Further-
more, recent studies have revealed a novel BAD phosphory-
lation site at S170 in cytokine-dependent MC/9 mast cells [14].
Importantly, BAD S170 is phosphorylated in response to
GM-CSF stimulation and the phosphorylation correlates
well with cell survival, although it remains uncertain which
kinase(s) is responsible for the phosphorylation. In this con-
text, phosphorylation of all these serine residues inactivates
BAD pro-apoptotic functions.
Recently, we have found that a human BAD mutant
(BADD119G) with a single amino acid substitution within
the BH3 domain can interact with Bcl-XL, but not with Bcl-
2. Interestingly, BADD119G displays a similar pro-apoptotic
activity to BADwt in serum-deprived COS-7 cells [15]. These
results are consistent with the previous suggestion that the
pro-apoptotic actions of BAD are primarily dependent on
neutralization of Bcl-XL, and that its neutralization of Bcl-2
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is marginal [6]. Further characterization of BADD119G
prompted us to realize that overexpression of BADD119G
somehow induced more extensive apoptosis in COS-7 cells
than in BADwt. This suggests that the mutation within the
BH3 domain might modulate its pro-apoptotic activity. To
explore this possibility, we further investigated BADD119G
functions and their regulation. We here demonstrate that
BADD119G loses phosphorylation-mediated negative regula-
tion and this may explain, at least in part, its stronger pro-
apoptotic activity.
2. Materials and methods
2.1. Cell culture
Three cell lines, green monkey kidney epithelial COS-7 and human
embryonal HEK 293, were obtained from the Japanese Cancer Re-
search Resources Bank (Tokyo, Japan) and grown in Dulbecco’s
modi¢ed Eagles medium (DMEM) supplemented with 10% fetal calf
serum (FCS) at 37‡C in 5% CO2.
2.2. Reagents and antibodies
TPA, forskolin (FK), okadaic acid (OA) and catalytic PKA subunit
were purchased from Sigma (St. Louis, Mo, USA). The mammalian
expression vectors described below were transfected into cells using
LipofectAMINE 2000 Reagent (Gibco Life and Technologies, MD,
USA). Antibodies against BAD, phospho-BAD (S112, 136 and 155)
and Akt were from Cell Signaling Technology (Beverly, MA, USA).
Ser75, 99 and 118 in human BAD are equivalent to Ser112, 136 and
155 in murine BAD, respectively. Antibodies against Hsc70 and hem-
agglutinin were from Santa Cruz Biotechnology Inc. (CA, USA) and
Roche (IN, USA), respectively.
2.3. Plasmids
Full-length human BAD cDNA (BADwt was kindly provided by
Dr. J.C. Reed of the Burnham Institute) and mutant BADD119G, in
which Asp119 was replaced with Gly, was generated as described
previously [15]. These cDNAs were sub-cloned into green £uorescence
protein (GFP) expression vectors pEGFPs (Clontech, CA, USA). The
14-3-3K cDNA was isolated from human placenta MATCHMAKER
cDNA library (Clontech) by a yeast two-hybrid system in our labo-
ratory (unpublished data). These cDNAs were also subcloned into the
prokaryote pGEX 4T expression vectors (Amersham Pharmacia Bio-
tech, IL, USA) for the generation of glutathione-S-transferase (GST)
fusion proteins. Constitutively active Akt (CA-Akt) cDNA expression
vector was kindly provided by Dr. M.E. Greenberg (Harvard Medical
School).
2.4. Apoptosis
To evaluate cell viability, cells were mixed with the same volume of
0.4% trypan blue solution, and immediately examined under the light
microscope for dye exclusion. The caspase-3 colorimetric protease
assay was performed following the manufacturer’s protocol (CPP32/
Caspase-3 Colorimetric Protease Assay kit, MBL, Nagoya, Japan).
Brie£y, 1U106 cells were lysed in 120 Wl of chilled lysis bu¡er and
incubated on ice for 10 min. Total cell lysates were collected and their
protein concentration measured using a Protein Assay (Bio-Rad, NY,
USA). The lysates (100 Wg) were mixed with the same volume of 2U
Reaction Bu¡er, incubated with the 4 mM DEVD-pNA caspase-3
substrate (200 WM ¢nal concentration) at 37‡C for 2 h, and then
analyzed at 400 nm in a spectrophotometer (Shimazu, Tokyo, Japan).
2.5. Western blot analysis
The 1U106 cells were lysed by the addition of 100 Wl of lysis bu¡er
containing 100 mM NaCl, 2 mM EDTA, 1 mM PMSF, 1% NP-40
and 50 mM Tris^HCl (pH 7.2). Total cell lysates (80 Wg/lane) were
separated in 15% sodium dodecyl sulfate^polyacrylamide gel electro-
phoresis (SDS^PAGE) gels and then electrophoretically transferred to
PVDF membranes (Millipore, MA, USA) at 20 V for 70 min. Mem-
branes were soaked into 8% BSA (Sigma) overnight at 4‡C and
washed with washing bu¡er containing 140 mM NaCl, 25 mM
Tris^HCl (pH 7.8) and 0.05% Tween 20. The membranes were incu-
bated with primary antibodies overnight at 4‡C and thereafter incu-
bated with the corresponding peroxidase-linked secondary antibodies
for 1 h at room temperature. Blots were visualized by an ECL system
(Amersham Pharmacia Biotech).
2.6. GST fusion protein expression and pull-down assays
pGEX plasmids encoding full-length BADwt, BADD119G, and 14-
3-3 as GST fusion proteins were generated as described above. The
fusion proteins were induced in BL21-bacteria with isopropyl-L-D-thi-
ogalactoside and were then puri¢ed with glutathione^Sepharose 4B
(Amersham Pharmacia Biotech). For control experiments GST alone
was generated from the pGEX-4T vector. The fusion protein-bound
beads were washed and resuspended in 10 mM Tris, pH 7.4, 150 mM
NaCl, 5% glycerol, 1% phenylmethylsulfonyl £uoride and 1 Wg/ml
leupeptin. The concentration of GST fusion protein bound to the
beads was estimated visually from Coomassie blue-stained SDS^
PAGE with albumin standards. For co-precipitation assays whole
cell lysates (1 mg) of HEK 293 transfected cells described above
were incubated with 20 Wl of GST fusion protein-bound beads for
1^2 h at 4‡C. The beads were washed at least ¢ve times with ice-
cold lysis bu¡er followed by separation via SDS^PAGE. Proteins
were then subjected to Western blot analysis.
2.7. In vitro kinase reactions
The in vitro kinase reactions were performed as described previ-
ously [16]. To de¢ne the ability of BADwt and BADD119G to be
phosphorylated, their GST fusion proteins were bound to gluta-
thione^Sepharose beads, washed three times with lysis bu¡er, twice
with kinase bu¡er (40 mM HEPES [pH 7.4], 3 mM MnCl2, 10 mM
Fig. 1. BAD overexpression induces apoptosis. COS-7 cells were
transiently transfected with control pEGFP vector (MOCK), GFP-
human BADwt or GFP-BADD119G and cultured in DMEM sup-
plemented with 10% FCS. A: Overexpression of GFP-BAD pro-
teins. 24 h after transfection, cells were harvested and subjected to
immunoblot analysis. Hsc70 shows the same amount of protein
loaded in each lane. B: BAD overexpression augmented cell death.
Cell death was evaluated at 24 h after transfection by trypan blue
exclusion assay. C: BAD overexpression increased caspase-3 activ-
ity. Transfectants were cultured for 8^16 h, and subjected to cas-
pase-3 measurement. The numbers represent the fold increase in ab-
sorbance at 400 nm relative to the mock transfectants harvested at
16 h after transfection. Each column (MOCK, open; BADwt,
closed; BADD119G, hatched) displays the meanTS.D. of data
from three separate experiments in panels B and C.
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MgCl2 and 1 mM DTT) and resuspended in 30 Wl of the kinase bu¡er.
The kinase reaction was initiated by the addition of PKA catalytic
subunit (7.5 units) and 100 WM ATP. Following 60 min incubation at
30‡C, the reactions were terminated by the addition of SDS loading
bu¡er, and the resultant samples were subjected to SDS^PAGE anal-
ysis. BAD phosphorylation was evaluated by antibodies against phos-
pho-BAD (S112 and 155).
3. Results
Previously, we demonstrated that both GFP-fused human
full-length wild-type BAD (BADwt) and its mutant
BADD119G induced apoptosis in serum-starved COS-7 trans-
fectants [15]. To further analyze their biological activity, we
¢rst compared their potential pro-apoptotic activity in serum-
containing COS-7 cells. Gene transfer of these BAD cDNA
expression vectors produced a substantial amount of protein
in both transfectants (Fig. 1A). Overexpression of BADwt
strongly induced cell death and increased caspase-3 activity
in a time-dependent manner in COS-7 transfectants (Fig. 1B,
C). Although the expression level of BADD119G was obvi-
ously less than that of BADwt, BADD119G showed a similar
pro-apoptotic potential to BADwt, as assessed by cell death
and activation of caspase-3 (Fig. 1B,C). Caspase-3 activity
was slightly higher in BADD119G transfectants at 12^16 h
than in BADwt transfectants (Fig. 1C). Thus, there was a
slight di¡erence between BADwt and BADD119G transfec-
tants when they were cultured in serum-containing medium.
However, a large di¡erence was observed in the apoptosis of
COS-7 cells co-transfected with CA-Akt. CA-Akt displayed
greater mobility than endogenous Akt due to deletion of its
negative-regulatory domain (Fig. 2A). Co-transfection of
BADwt with CA-Akt signi¢cantly suppressed BADwt-medi-
ated augmentation of cell death and caspase-3 activity
(Fig. 2B,C). In contrast, co-transfection with CA-Akt did
not suppress BADD119G-mediated augmentation of apopto-
sis, although CA-Akt expression was greater than in BADwt-
co-transfectants. Consideration of previous ¢ndings that BAD
pro-apoptotic activity is strongly inhibited by Akt activation
through its direct phosphorylation of BAD [11,12] and the
loss of sensitivity to Akt activation in BADD119G transfec-
tants suggest that BADD119G may abrogate Akt-mediated
phosphorylation. We therefore investigated the phosphoryla-
tion level of BAD in both CA-Akt-BADwt and CA-Akt-
BADD119G co-transfectants. CA-Akt co-transfection clearly
increased BADwt phosphorylation levels at S75 and S99
(equivalent to S112 and S136 in murine BAD, respectively),
whereas phosphorylation of BADD119G was not visible
(Fig. 2A). Even overexpression of CA-Akt failed to phosphor-
ylate BADD119G. This is probably because of insensitivity of
BADD119G to CA-Akt. To explore whether this happens in
other cells, we investigated the e¡ect of CA-Akt overexpres-
sion on BADD119G-mediated apoptosis in NIH3T3 cells. As
observed in COS-7 cells, sensitivity of BADD119G to Akt was
also impaired (data not shown), suggesting that this defect is a
general one regardless of cell type.
We further explored whether BADD119G loses its ability to
Fig. 2. BADD119G mutant was resistant to CA-Akt overexpression. COS-7 cells were transiently transfected with pEGFP (MOCK), GFP-
BADwt (BAD), or GFP-BADD119G (D119G) expression vectors. A: Expression of BAD with CA-Akt proteins and BAD phosphorylation.
Transfectants were cultured with FCS, harvested at 21 h after co-transfection either with (+) or without (3) the CA-Akt expression vector and
subjected to Western blot analysis. Hsc70 shows the same amount of protein loaded in each lane. B: E¡ect of CA-Akt on BAD-mediated cell
death. At 21 h after transfection, cell death was evaluated by trypan blue exclusion assay. C: E¡ect of CA-Akt on BAD-induced caspase-3 acti-
vation. At 12 h after co-transfection, caspase-3 activity was measured. The numbers represent the fold increase in absorbance at 400 nm relative
to the mock transfectants. In panels B and C, COS-7 cells were transfected with the indicated vectors together with CA-Akt (closed columns)
or its vehicle (open columns). Each column displays the meanTS.D. of data from three separate experiments.
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be phosphorylated e⁄ciently due to various external stimuli.
In COS-7 cells, TPA and UV exposure strongly increased
phosphorylation levels of BADwt at S75, S99 and S118
(equivalent to S155 in murine BAD) phosphorylation sites
(Fig. 3A). However, these stimuli did not increase phosphor-
ylation levels of BADD119G as seen with BADwt, although
TPA faintly increased phosphorylation at S75 only. Impor-
tantly, these stimuli clearly phosphorylated intrinsic BAD at
S112 even in BADD119G-expressing transfectants as ob-
served in BADwt transfectants (arrow in Fig. 3A). We next
investigated the e¡ect of 10 WM FK, which increases cAMP
levels and activates PKA, on the phosphorylation of BADs,
since PKA is the serine/threonine kinase responsible for S112
and S155 phosphorylation of murine BAD [17^19]. In COS-7
transfectants, FK treatment clearly increased phosphorylation
levels of BADwt at S75 and S118, but not those of
BADD119G (Fig. 3B). To explore whether the observed
lack of phosphorylation of BADD119G in COS-7 cells is
general, we further investigated the e¡ect of FK treatment
on phosphorylation levels of BADD119G in HeLa transfec-
tant cells. As observed in COS-7 cells, both serines of
BADD119G were not phosphorylated by FK as e⁄ciently
as BADwt (data not shown). To explore the molecular mech-
anism(s) by which the BADD119G lost phosphorylation-
mediated regulation, we investigated the e¡ect of OA on its
phosphorylation levels. OA strongly inhibits PP2A and
weakly inhibits PP1, both of which are involved in the de-
phosphorylation of BAD [20,21]. Although OA treatment
clearly increased basal phosphorylation of intrinsic BAD at
S112 in COS-7 cells (arrow in Fig. 3C), it did not increase
BADD119G phosphorylation (Fig. 3C), making it unlikely
that either PP2A or PP1 phosphatase activity contributes to
decreased phosphorylation levels in BADD119G. We next
investigated whether BADD119G can be phosphorylated by
PKA in vitro, since the mutation at S119 may disrupt PKA-
mediated phosphorylation at S118. The GST^BADwt and
GST^BADD119G fusion proteins [15] were used as exoge-
nous substrates in an in vitro kinase assay with the PKA
catalytic subunit. An in vitro kinase assay revealed that
both fusion proteins were strongly phosphorylated by cata-
lytic PKA, although S118 of GST^BADD119G was slightly
less phosphorylated (Fig. 3D). This strongly suggests that the
mutation at S119 did not totally disrupt the ability of S118 to
be phosphorylated by PKA. These data indicate that the mu-
tant BADD119G has a defect in its phosphorylation at all
three major phosphorylation sites, and probably this defect
causes insensitivity to CA-Akt and sustained pro-apoptotic
activity.
Phosphorylated BAD is inactivated by its direct interaction
with 14-3-3 and their physical interaction prevents BAD from
Fig. 3. Phosphorylation of BADwt (BAD) and BADD119G (D119G). A: TPA and UV exposure cannot phosphorylate BADD119G e¡ectively.
COS-7 cells were transfected with the indicated expression vectors. After 12 h, cells were deprived of FCS for 10 h, treated with 100 nM TPA
or exposed to 40 J/m2 UV and harvested at indicated hours. B: FK treatment cannot phosphorylate BADD119G. After 12 h serum depriva-
tion, COS-7 transfectants were treated with 20 WM FK for the indicated time. C: OA has no signi¢cant e¡ect on phosphorylation of
BADD119G. At 4 h after transfection, medium was refreshed and COS-7 transfectant cells were further cultured in the presence (+) or absence
(3) of 20 nM OA for 14 h. In panels A^C, cells were harvested, and Western blot analysis was carried out using anti-phospho-BAD S112
(75), S136 (99) or S155 (118) antibodies or control BAD antibody. In panels A and C, arrows indicate strong phosphorylation of intrinsic
BAD at S112 in COS-7 cells. D: In vitro phosphorylation of GST^BAD proteins. PKA catalytic subunit (7.5 unit) was incubated with GST^
BADwt (BAD) or GST^BADD119G (D119G) for 30 min at 25‡C. PKA-mediated phosphorylation of these substrates was evaluated by West-
ern blot analysis. Loaded substrates were visualized by separation on 12% SDS^PAGE and staining with Coomassie brilliant blue R-250
(GST^BAD).
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targeting mitochondria [6,7,22]. It is thus likely that
BADD119G cannot interact with 14-3-3. To study this possi-
bility, we carried out a GST pull-down analysis. The GST^14-
3-3K fusion proteins were immobilized on glutathione beads
(Fig. 4A), and incubated with cell lysates of BADwt or
BADD119G-expressing HEK 293 cells, which are resistant
to BAD overexpression (data not shown). Western blot anal-
ysis revealed the speci¢c pull-down of BADwt, but not
BADD119G, by 14-3-3K (Fig. 4B). In addition, the impaired
interaction between BADD119G and 14-3-4K could not be
restored by FK treatment. Thus, BADD119G lost its ability
to interact with 14-3-3 proteins as a result of its impaired
phosphorylation.
4. Discussion
Here, we demonstrate that a single amino acid mutation of
BAD within its BH3 domain impairs its phosphorylation at
all major phosphorylation sites and allows its pro-apoptotic
activity to persist even in transfectants overexpressing CA-
Akt. In this regard, BADD119G is resistant to its inhibitor
kinase Akt. The accumulating data showing that Akt is
strongly activated in many primary cancer cells [23^25] sug-
gest that BADD119G may introduce apoptotic signals into
these carcinomas.
In this study, we found that a single amino acid 119D sub-
stitution within the BH3 domain of BAD extensively de-
stroyed its ability to be phosphorylated and to interact with
14-3-3. Indeed, BADD119G is hypo- or un-phosphorylated in
COS-7, NIH3T3 and HeLa cells and its phosphorylation is
only faintly detectable even after stimulation with UV, TPA
and FK treatment. In contrast, substitution of alanine for
leucine (L; another well-conserved amino acid residue) within
the BH3 domain of BAD strongly reduces its ability to inter-
act with Bcl-XL or Bcl-2, but increases its interaction with 14-
3-3 to a greater extent than BADwt [8]. Together with the
data showing its retarded mobility on SDS^PAGE, the au-
thors suggested that the mutated BAD at the L residue may
be somehow highly phosphorylated and this hyper-phosphor-
ylation may explain its strong interaction with 14-3-3 and
subsequent loss of pro-apoptotic functions. These data sug-
gest that the BH3 domain of BAD is a crucial site, not only
for interaction with other Bcl-2 family members, but also for
its own phosphorylation machinery.
It remains obscure why the mutant BADD119G loses its
ability to be phosphorylated. Our preliminary studies exclude
the possibility that increased dephosphorylation is involved in
the mechanism, since there was no signi¢cant e¡ect of the PP1
inhibitor OA on phosphorylation levels of BADD119G,
although OA strongly increased phosphorylation levels of in-
trinsic BAD at S75. Furthermore, mutation at the D residue
did not totally destroy acceptor sites for kinases, since in vitro
kinase assay revealed that PKA strongly phosphorylated both
BADs (S75 and S118). At this point, we believe that the mu-
tation at the 119D residue within the BH3 domain probably
changes its whole BAD conformation and blocks its accessi-
bility to responsible kinases in vivo. In this regard, our study
highlights the importance of the three-dimensional conforma-
tion of the BH3 domain of BAD. According to its predicted
structure, the acidic 119D residue is located at the center of
the BH3 domain, and is surrounded by basic residues R and
K [8]. We speculate that these charged residues might be cru-
cial for maintenance of its entire BAD conformation.
A recent study has revealed that Cdc2 kinase phosphory-
lates murine BAD at S128 and inhibits the interaction of
BAD with 14-3-3 proteins in cerebellar neurons [26]. This
indicates that the novel and distinct BAD phosphorylation
at S128 activates its pro-apoptotic functions. In this context,
BAD phosphorylation regulates its pro-apoptotic functions
either positively or negatively. Interestingly, BADD119G dis-
played a slower mobility on SDS^PAGE than BADwt. This
allows us to consider that BADD119G may be aberrantly
phosphorylated and survival signal-mediated phosphorylation
may be disrupted at S75, S99 and S118. Disregarding the
precise molecular mechanism for un-phosphorylation at these
sites of BADD119G, our data indicate that the acidic D res-
Fig. 4. Interaction of human BAD (BAD) or BADD119G (D119G) with 14-3-3K. A: Expression of GST or GST^14-3-3 fusion proteins. Total
GST fusion protein amounts per bead were estimated virtually using Coomassie blue-stained SDS^PAGE. Molecular size marker (M) is shown
in kDa. B: Speci¢c binding of BADwt, but not BADD119G, to the GST^14-3-3K fusion proteins. Cell lysates (1 mg) from HEK 293 cells
transfected with GFP-tagged BAD or BADD119G expression vector were passed over GST or GST^14-3-3 beads. The bound proteins were
separated via SDS^PAGE and identi¢ed by Western blots using anti-BAD antibody as a probe. Total proteins loaded are shown in the upper
panel (INPUT). To investigate the e¡ect of FK, HEK 293 transfectants were stimulated by 100 nM FK (+) and harvested at 30 min after the
treatment.
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idue is crucial for phosphorylation-mediated negative regula-
tion of BAD.
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